BioSpace News Archive

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data presentations at the American College of Neuropsychopharmacology (ACNP) 62nd Annual Meeting.

Stryker announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable January 31, 2024 to shareholders of record at the close of business on December 29, 2023, representing an increase of 6.7% versus the prior year and previous quarter.

Aspargo Laboratories, Inc. announced the completion of dosing of all 53 subjects in two cohorts in the Company’s comparative bioavailability study, comparing Sildenafil Oral Suspension to Viagra®.

IntelGenx Technologies Corp. announces the closing of the previously announced subsequent non-brokered private placement of 750 units with atai Life Sciences AG for aggregate gross proceeds of US$750,000, on the same terms as the August 31, 2023, offering of units, following the Shareholder Approvals obtained at the special meeting held on November 28, 2023.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today reported that it met its primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of its randomized, placebo-controlled, double-blind segment the Company’s Phase 2b amyotrophic lateral sclerosis (“ALS”) trial of PrimeC (“PARADIGM”).

Nasus Pharma Ltd a clinical-stage biopharmaceutical company focused on developing a needle-free, powder-based Intranasal (PBI) product portfolio to address acute medical conditions announced positive results from its latest clinical study of intranasal powder-based Epinephrine.

Evolution Optiks Limited, a privately held company and forerunner in light field technology, announced today the successful completion of data collection in a US FDA-authorized clinical study to assess the safety and efficacy of its DeCon device for the evaluation of human vestibular disorders.

ProfoundBio announced that management will be participating in one-on-one meetings with investors at the 2023 RBC Capital Markets Healthcare Private Company Conference, being held virtually December 13-14, 2023.

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced the pricing of an underwritten public offering of 9,482,758 shares of its common stock at a public offering price of $29.00 per share.

J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI ‘JIN-A02' were presented at the ESMO Asia 2023 conference held in Singapore from 1st to 3rd December 2023.